Answers are grounded in this paper and cite their sources.
Histotripsy is an emerging noninvasive therapeutic ultrasound technique that uses acoustic cavitation to mechanically destroy targeted tissue, offering an alternative to traditional surgery and percutaneous interventions. Compared with thermal ablation, histotripsy achieves precise tissue destruction without relying on heat, producing sharper boundaries between treated and untreated regions, offering tissue selectivity for critical structures, and enhancing immunomodulatory effects. Recent clinical trials have demonstrated its potential in treating liver tumors, kidney tumors, and benign prostatic hyperplasia, with recent Food and Drug Administration approval of the first commercial histotripsy platform for liver tumors. Wider clinical adoption of histotripsy will rely on continued technical advances in treatment planning, navigation, and imaging guidance, ensuring safety and efficacy. Future developments such as artificial intelligence (AI)-assisted treatment planning, real-time feedback, and robotic navigation are expected to enhance its clinical utility. A better understanding of the immunomodulatory response and effectiveness as a combination therapy may further expand its applications. This article explores the physical mechanisms, clinical applications, and future potential of histotripsy for ablation, focusing on oncology and the technical and procedural advancements needed for its broader adoption in clinical practice.
No takes yet. Share an insight, caveat, or question.
Howell et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: